Coya Therapeutics (COYA) Set to Post Earnings on Wednesday

Posted by Brenda Bartman on Nov 4th, 2026

Coya Therapeutics (NASDAQ:COYA – Get Free Report) is projected to issue its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to post earnings of ($0.35) per share and revenue of $0.11 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.07. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts expect Coya Therapeutics to post ($1.34) EPS for the current fiscal year and ($1.94) EPS for the next fiscal year.

Coya Therapeutics Trading Up 4.5%

Shares of NASDAQ COYA opened at $3.25 on Wednesday. Coya Therapeutics has a twelve month low of $3.03 and a twelve month high of $6.62. The company has a market capitalization of $76.25 million, a price-to-earnings ratio of -3.04 and a beta of 0.70. The firm has a 50-day moving average of $4.54 and a two-hundred day moving average of $4.63.

Wall Street Analysts Forecast Growth

COYA has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. Chardan Capital reissued a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Roth Capital restated a “buy” rating and set a $12.00 target price on shares of Coya Therapeutics in a report on Monday, August 24th. BTIG Research restated a “buy” rating and issued a $16.00 price target on shares of Coya Therapeutics in a research report on Tuesday, September 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.33.

Check Out Our Latest Research Report on COYA

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.